Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.

07/13/2026, 1:00 PM • GlobeNewswire

Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece

Cosmos Health has partnered with Libytec Pharmaceutical to commercialize DIABIT-IS X (sitagliptin), a generic diabetes medication, in Greece. Under a five-year agreement, Cosmos will supply the drug while Libytec handles distribution and promotion. As a prescription medicine covered by Greece's national health insurance system, DIABIT-IS X is positioned to reach a broad patient population and contribute meaningfully to revenue and cash flow.

07/13/2026, 1:00 PM • GlobeNewswire

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?

Vanguard Health Care ETF (VHT) offers broad diversification across 429 healthcare holdings with a low 0.09% expense ratio, while VanEck Pharmaceutical ETF (PPH) provides concentrated exposure to 26 drugmakers with higher returns but greater risk. VHT is more cost-effective and diversified, while PPH has delivered superior 5-year returns and higher dividend yield despite concentration risk and a higher 0.36% expense ratio.

07/09/2026, 8:15 AM • The Motley Fool

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with 25 concentrated holdings and State Street SPDR S&P Pharmaceuticals ETF (XPH) with 65 diversified holdings. Both charge identical 0.35% expense ratios and offer 0.50% dividend yields, but XPH delivered significantly higher 1-year returns (64.30% vs 33.30%) and lower volatility, making it potentially more suitable for beginners seeking diversification.

07/08/2026, 7:28 AM • The Motley Fool

The Dividend ETF Quietly Outperforming the S&P 500

The iShares Core High Dividend ETF (HDV) has gained over 15% year-to-date, outperforming the S&P 500's 9% return. The fund's success is driven by its high-quality dividend stock selection and significant exposure to energy stocks (ExxonMobil, Chevron) and healthcare stocks (AbbVie, Merck), which have all posted strong gains. HDV's focus on financially healthy companies with sustainable competitive advantages has delivered consistent returns over multiple time periods.

07/07/2026, 5:30 AM • The Motley Fool

Moderna Stock Is Soaring. Is It Too Late to Buy?

Moderna's stock has more than doubled this year as the company transitions from a COVID-19 vaccine maker to a diversified biotech firm. With multiple late-stage vaccine programs (flu, norovirus, combination vaccines) and cancer therapies in development, the company is preparing for major product launches in 2027-2028. Strong financials including $7.5 billion in cash and improving revenue support long-term growth potential, though recent gains reflect high expectations and clinical risks remain.

07/07/2026, 5:15 AM • The Motley Fool

3 Dividend ETF Picks That Could Build Serious Long-Term Wealth

The article examines three dividend-focused ETFs as wealth-building alternatives to growth stocks. SCHD offers higher yields through value-oriented dividend stocks, VIG combines growth potential with rising dividends, and DGRO provides a balanced hybrid approach. All three can build serious long-term wealth through dividend reinvestment if held patiently.

07/05/2026, 5:20 PM • The Motley Fool

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

Moderna and Recursion Pharmaceuticals represent two distinct approaches to biotech innovation: Moderna leverages proven mRNA technology with diversifying pipeline into oncology and rare diseases, while Recursion uses AI-driven drug discovery. Despite both operating at losses, Moderna is favored for 2026 due to its established revenue base and proven formula, whereas Recursion remains in earlier development stages with revenue expected to decline due to lower milestone payments.

07/03/2026, 11:14 AM • The Motley Fool

Want Decades of Passive Income? Buy This ETF and Hold It Forever.

The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a long-term holding for passive income, offering a 3.25% dividend yield—more than three times the S&P 500's 1.07%. The ETF tracks 100 dividend-paying companies with at least 10 years of consecutive dividend payments and has seen its payout rise 211% over the past decade. Year-to-date performance shows 18.9% total return versus the S&P 500's 8.1%.

07/03/2026, 7:27 AM • The Motley Fool

Big Pharma Has a Case of Merger Mania

The pharmaceutical industry is experiencing a record-breaking M&A wave in 2026, driven by looming patent cliffs worth $300 billion in annual revenue, FDA regulatory improvements for rare diseases, and the need to diversify portfolios. Companies are making strategic bolt-on acquisitions of late-stage drug candidates rather than massive mergers. While some firms like Eli Lilly are well-positioned, others like Merck and Pfizer face near-term patent expirations that could impact revenue significantly.

06/30/2026, 12:26 AM • The Motley Fool

Global HPV Vaccines Market to Grow Rapidly at a CAGR of ~8% by 2034 | DelveInsight

The global HPV vaccines market is projected to grow from USD 8.9 billion in 2025 to USD 18.4 billion by 2034, driven by rising HPV-associated cancer prevalence, expanding government immunization programs, and advancements in multivalent vaccines. North America leads the market with 41% share, while Asia-Pacific emerges as a significant growth contributor. Key developments include Merck's presentation of long-term vaccine effectiveness data and China's approval of the first domestically-developed 9-valent HPV vaccine.

06/24/2026, 1:00 PM • GlobeNewswire

Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda

Questex's Fierce Life Sciences announced the agenda for the 16th annual PODD (Partnership Opportunities in Drug Delivery) Conference, scheduled for October 29-30, 2026, in Boston. The event will gather over 1,000 industry executives and features 150+ sessions with keynotes from Regeneron's Dr. George Yancopoulos and MIT's Dr. Robert Langer, covering topics including AI in drug delivery, pharma partnering strategies, and reimbursement challenges.

06/23/2026, 8:00 AM • GlobeNewswire

Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight

The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I interferon pathways are expected to transform treatment options for CLE patients.

06/22/2026, 1:00 PM • GlobeNewswire

Moderna Has Some Key Approvals Ahead. Is the Stock a Buy?

Moderna's stock has surged over 100% this year as the company diversifies beyond COVID-19 vaccines using its mRNA platform. Key catalysts include FDA approval of mFlusiva (flu vaccine) expected August 5, 2026, and the European Commission's approval of mCOMBRIX (flu-COVID combination vaccine). The company's most transformative opportunity lies in cancer vaccines, with phase 3 data for mRNA-4157 expected later in 2026. Despite 260% revenue growth in Q1 2026, Moderna remains unprofitable but has $7.5 billion in cash and targets company-wide breakeven by 2028.

06/20/2026, 7:30 AM • The Motley Fool

Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook

Pfizer stock fell 2.74% following the announcement that CFO Dave Denton will depart in August, raising investor concerns about leadership continuity and the company's ability to meet 2026 guidance. While recent drug approvals strengthen the pipeline, the CFO transition creates uncertainty around financial execution and earnings recovery.

06/18/2026, 7:09 PM • The Motley Fool